About: Modified vaccinia virus Ankara as a vaccine against feline coronavirus: immunogenicity and efficacy

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Modified vaccinia virus Ankara as a vaccine against feline coronavirus: immunogenicity and efficacy Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Modified vaccinia virus Ankara as a vaccine against feline coronavirus: immunogenicity and efficacy
Creator	Aubert, André Cronier, Joëlle Duquesne, Véronique Hebben, Matthias Rossi, Bernard
topic	covid:7ba0c95a0fd9545009ff870fa5e317b5c1ad725b#this
source	Elsevier; Medline; PMC
abstract	Abstract Feline infectious peritonitis virus (FIPV) is a coronavirus that induces a fatal systemic disease mediated by an inappropriate immune response. Most previous vaccination attempts against FIPV were unsuccessful because IgG antibodies against the surface protein enhance the infection. However, two studies have shown that poxvirus vectors (vaccinia WR and canarypox) expressing only the FIPV membrane (M) protein can elicit a partially protective immunity which is supposed to be cell-mediated (Virology 181 (1991) 327; International patent WO 97/20054 (1997)). In our study, we report the construction of another poxvirus, the modified vaccinia virus Ankara (MVA), as an expression vector for the FIPV M protein. In this vector, the M gene has been inserted downstream a strong early/late promoter, whereas the two previously described poxviruses expressed the M protein during their early stage only. The immunogenicity of the recombinant MVA-M was evaluated in the murine model which revealed an effect of the vector on the Th1/Th2 balance. The vaccine was then tested in cats to evaluate its efficacy in an FIPV 79-1146 challenge. Vaccinated kittens developed FIPV-specific antibodies after immunization, however, none of them was protected against FIPV. Our results suggest a crucial role for the type of poxviral promoter that must be used to induce an effective immune response against FIPV.
has issue date	2004-04-30(xsd:dateTime)
bibo:doi	10.1016/j.jfms.2003.12.011
bibo:pmid	15123156
has license	els-covid
sha1sum (hex)	7ba0c95a0fd9545009ff870fa5e317b5c1ad725b
schema:url	https://doi.org/10.1016/j.jfms.2003.12.011
resource representing a document's title	Modified vaccinia virus Ankara as a vaccine against feline coronavirus: immunogenicity and efficacy
has PubMed Central identifier	PMC7128240
has PubMed identifier	15123156
schema:publication	Journal of Feline Medicine & Surgery
resource representing a document's body	covid:7ba0c95a0fd9545009ff870fa5e317b5c1ad725b#body_text
is http://vocab.deri.ie/void#inDataset of	https://covidontheweb.inria.fr:4443/about/id/http/ns.inria.fr/covid19/7ba0c95a0fd9545009ff870fa5e317b5c1ad725b
is schema:about of	named entity 'IMMUNOGENICITY' named entity 'induce' named entity 'revealed' named entity 'inserted' named entity 'Th2' named entity 'M protein' named entity 'developed' named entity 'murine' named entity 'vaccine' named entity 'evaluate' named entity 'immunization' named entity 'vaccine' named entity 'vaccinia virus' named entity 'IMMUNIZATION' named entity 'USED' named entity 'VACCINE' named entity 'DESCRIBED' named entity 'MVA' named entity 'EFFICACY' named entity 'EVALUATE' named entity 'MEMBRANE' named entity 'VECTORS' named entity 'PROTECTIVE IMMUNITY' named entity 'VACCINE' named entity 'STUDY' named entity 'THEIR' named entity 'ROLE' named entity 'EXPRESSION VECTOR' named entity 'EXPRESSED' named entity 'PREVIOUS' named entity 'EFFECT' named entity 'TH1' named entity 'INFECTION' named entity 'MEDIATED' named entity 'CHALLENGE' named entity 'PROMOTER' named entity 'IGG' named entity 'PROTEIN CAN' named entity 'ELICIT' named entity 'IS A' named entity 'MURINE' named entity 'POXVIRUS' named entity 'PROTEIN ' named entity 'INDUCE' named entity 'EFFICACY' named entity 'EVALUATED' named entity 'TYPE' named entity 'REPORT' named entity 'STUDIES' named entity 'VACCINIA VIRUS ANKARA' named entity 'FELINE CORONAVIRUS' named entity 'INSERTED' named entity 'M PROTEIN' named entity 'RESULTS' named entity 'SUGGEST' named entity 'SURFACE PROTEIN' named entity 'MODIFIED' named entity 'PATENT' named entity 'REVEALED' named entity 'MODIFIED' named entity 'POXVIRUSES' named entity 'BE CELL' named entity 'EARLY STAGE' named entity 'VACCINIA VIRUS ANKARA' named entity 'FELINE INFECTIOUS PERITONITIS VIRUS' named entity 'INTERNATIONAL' named entity 'DOWNSTREAM' named entity 'UNSUCCESSFUL' named entity 'VACCINATION' named entity 'EARLY' named entity 'SYSTEMIC DISEASE' named entity 'VACCINATED' named entity 'TESTED' named entity 'FATAL' named entity 'IMMUNE RESPONSE'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software